Selective opioid agonist Taphalgin® as a component of postoperative analgesia in various surgical areas: “NIKITA” observational multicenter study

A.E. Karelov(Ministry of Health of the Russian Federation), Yu. N. Kraevskaya(V.A. Negovsky Scientific Research Institute of General Reanimatology), N. P. Shevchenko(Oncological Dispensary No. 2), А. М. Овезов, А. С. Сорокин(Plekhanov Russian University of Economics), M. I. Alexandrov(City Clinical Hospital No. 2), A.V. Boyarkov(Moscow Clinical Scientific Center), В. Э. Хороненко(Ministry of Health of the Russian Federation), И. В. Шаймарданов(Republican Oncological Clinical Dispensary), O. Yu. Gamzeleva, С. А. Божкова(Unknown), Т. С. Мусаева, Г. Р. Абузарова(Ministry of Health of the Russian Federation), T. V. Klypa(Federal Medical-Biological Agency), И. Б. Заболотских(Kuban State Medical University), D. V. Yemelyanov(Nizhny Novgorod Regional Clinical Oncology Center), E. V. Neduruyev(Ministry of Health of the Russian Federation), G. S. Solovyov, Г. В. Родоман(Pirogov Russian National Research Medical University), S. A. Ilyin, А. Л. Потапов(Medical Radiological Research Center)
Head and neck tumors (HNT)
August 3, 2024
Cited by 5


Related Papers